Biohaven Ltd
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
BHVN$15.11-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(659,579) | $(263,412) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 5,394 | 5,018 |
| Non-cash share-based compensation | 59,269 | 12,916 |
| Issuance of common shares as payment for acquisition of IPR&D asset | 10,811 | — |
| Issuance of common shares as payment under license and other agreements | 71,627 | — |
| Fair value of forward contract and derivative liabilities under license agreement | 102,529 | — |
| Change in fair value of forward contract and derivative liabilities | (21,179) | — |
| Issuance of warrant under license agreement | 3,340 | — |
| Other non-cash items, net | (6,749) | (4,696) |
| Changes in operating assets and liabilities, net of effects of acquisition: | ||
| Prepaid expenses and other current and non-current assets | (290) | 28,428 |
| Accounts payable | 2,425 | (1,188) |
| Accrued expenses and other current and non-current liabilities | 20,691 | 6,090 |
| Net cash used in operating activities | (411,711) | (216,844) |
| Cash flows from investing activities: | ||
| Proceeds from maturities of marketable securities | 312,364 | 214,224 |
| Proceeds from sales of marketable securities | — | 4,920 |
| Purchases of marketable securities | (466,053) | (82,822) |
| Purchases of property and equipment | (4,000) | (2,578) |
| Cash acquired from acquisition of IPR&D asset | 391 | — |
| Net cash (used in) provided by investing activities | (157,298) | 133,744 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common shares | 394,881 | — |
| Payment of issuance costs | (800) | — |
| Change in restricted cash due to Former Parent | — | (35,184) |
| Proceeds from equity incentive plan and employee share purchase plan | 8,582 | — |
| Other financing activities, net | 2,258 | 1,857 |
| Net cash provided by (used in) financing activities | 404,921 | (33,327) |
| Effects of exchange rates on cash, cash equivalents, and restricted cash | (13) | (187) |
| Net decrease in cash, cash equivalents, and restricted cash | (164,101) | (116,614) |
| Cash, cash equivalents, and restricted cash at beginning of period | 252,120 | 242,604 |
| Cash, cash equivalents, and restricted cash at end of period | $88,019 | $125,990 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.